Does the media favor HRTX or DARE?

In the previous week, Dare Bioscience had 2 more articles in the media than Heron Therapeutics. MarketBeat recorded 6 mentions for Dare Bioscience and 4 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 0.69 beat Dare Bioscience's score of 0.31 indicating that Heron Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Heron Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dare Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to DARE or ELOX?

In the previous week, Dare Bioscience had 3 more articles in the media than Eloxx Pharmaceuticals. MarketBeat recorded 6 mentions for Dare Bioscience and 3 mentions for Eloxx Pharmaceuticals. Eloxx Pharmaceuticals' average media sentiment score of 0.45 beat Dare Bioscience's score of 0.31 indicating that Eloxx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dare Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Eloxx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, DARE or ATHE?

Dare Bioscience has higher revenue and earnings than Alterity Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dare Bioscience $1.37M 10.50 -$13.40M -$0.70 N/A Alterity Therapeutics N/A N/A -$15.88M N/A N/A

Does the media refer more to DARE or ATHE?

In the previous week, Dare Bioscience had 4 more articles in the media than Alterity Therapeutics. MarketBeat recorded 6 mentions for Dare Bioscience and 2 mentions for Alterity Therapeutics. Alterity Therapeutics' average media sentiment score of 0.89 beat Dare Bioscience's score of 0.31 indicating that Alterity Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dare Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer DARE or INCR?

Dare Bioscience currently has a consensus target price of $6.50, indicating a potential upside of 791.63%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Dare Bioscience is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, DARE or INCR?

InterCure has higher revenue and earnings than Dare Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dare Bioscience $1.37M 10.50 -$13.40M -$0.70 N/A InterCure $270.20M 0.19 -$10.37M N/A N/A

Which has preferable valuation & earnings, DARE or TLPH?

Dare Bioscience has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dare Bioscience $1.37M 10.50 -$13.40M -$0.70 N/A Talphera $30K 1,834.15 -$14.29M -$0.27 N/A

Is DARE or TLPH more profitable?

Talphera has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. Talphera's return on equity of -87.28% beat Dare Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Dare Bioscience -803.80% -748.30% -38.75% Talphera N/A -87.28% -51.36%

Does the media favor DARE or TLPH?

In the previous week, Dare Bioscience had 4 more articles in the media than Talphera. MarketBeat recorded 6 mentions for Dare Bioscience and 2 mentions for Talphera. Talphera's average media sentiment score of 1.25 beat Dare Bioscience's score of 0.31 indicating that Talphera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dare Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Talphera 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Dare Bioscience (DARE) Competitors

$0.74 +0.01 (+1.51%)

Closing price 04:00 PM Eastern

Extended Trading

$0.74 -0.01 (-0.68%)

As of 04:56 PM Eastern

Compare

DARE vs. HRTX, ELOX, ATHE, INCR, and TLPH

Should you buy Dare Bioscience stock or one of its competitors? Dare Bioscience's main competitors and comparable companies include Heron Therapeutics (HRTX), Eloxx Pharmaceuticals (ELOX), Alterity Therapeutics (ATHE), InterCure (INCR), and Talphera (TLPH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Dare Bioscience compare to Heron Therapeutics?

Heron Therapeutics (NASDAQ:HRTX) and Dare Bioscience (NASDAQ:DARE) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

Heron Therapeutics has a net margin of -22.52% compared to Dare Bioscience's net margin of -803.80%. Heron Therapeutics' return on equity of -293.02% beat Dare Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-22.52%	-293.02%	-10.00%
Dare Bioscience	-803.80%	-748.30%	-38.75%

In the previous week, Dare Bioscience had 2 more articles in the media than Heron Therapeutics. MarketBeat recorded 6 mentions for Dare Bioscience and 4 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 0.69 beat Dare Bioscience's score of 0.31 indicating that Heron Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Heron Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dare Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dare Bioscience has lower revenue, but higher earnings than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$154.90M	0.44	-$20.19M	-$0.19	N/A
Dare Bioscience	$1.37M	10.50	-$13.40M	-$0.70	N/A

Heron Therapeutics presently has a consensus price target of $2.00, suggesting a potential upside of 452.49%. Dare Bioscience has a consensus price target of $6.50, suggesting a potential upside of 791.63%. Given Dare Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Dare Bioscience is more favorable than Heron Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Heron Therapeutics has a beta of 1.62, suggesting that its share price is 62% more volatile than the broader market. Comparatively, Dare Bioscience has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market.

80.0% of Heron Therapeutics shares are held by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are held by institutional investors. 6.1% of Heron Therapeutics shares are held by insiders. Comparatively, 3.4% of Dare Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Heron Therapeutics beats Dare Bioscience on 9 of the 16 factors compared between the two stocks.

How does Dare Bioscience compare to Eloxx Pharmaceuticals?

Dare Bioscience (NASDAQ:DARE) and Eloxx Pharmaceuticals (NASDAQ:ELOX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.

Dare Bioscience has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market. Comparatively, Eloxx Pharmaceuticals has a beta of -1960.42, suggesting that its share price is 196,142% less volatile than the broader market.

6.7% of Dare Bioscience shares are owned by institutional investors. Comparatively, 2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. 3.4% of Dare Bioscience shares are owned by insiders. Comparatively, 25.9% of Eloxx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Dare Bioscience had 3 more articles in the media than Eloxx Pharmaceuticals. MarketBeat recorded 6 mentions for Dare Bioscience and 3 mentions for Eloxx Pharmaceuticals. Eloxx Pharmaceuticals' average media sentiment score of 0.45 beat Dare Bioscience's score of 0.31 indicating that Eloxx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dare Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eloxx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dare Bioscience presently has a consensus target price of $6.50, suggesting a potential upside of 791.63%. Eloxx Pharmaceuticals has a consensus target price of $38.33, suggesting a potential upside of 213.95%. Given Dare Bioscience's higher probable upside, analysts clearly believe Dare Bioscience is more favorable than Eloxx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Eloxx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

Eloxx Pharmaceuticals has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. Eloxx Pharmaceuticals' return on equity of 0.00% beat Dare Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	-803.80%	-748.30%	-38.75%
Eloxx Pharmaceuticals	N/A	N/A	N/A

Eloxx Pharmaceuticals has higher revenue and earnings than Dare Bioscience. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.37M	10.50	-$13.40M	-$0.70	N/A
Eloxx Pharmaceuticals	$6.36M	7.76	-$5.99M	-$1.54	N/A

Summary

Eloxx Pharmaceuticals beats Dare Bioscience on 9 of the 15 factors compared between the two stocks.

How does Dare Bioscience compare to Alterity Therapeutics?

Dare Bioscience (NASDAQ:DARE) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

Dare Bioscience has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market.

Alterity Therapeutics has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. Alterity Therapeutics' return on equity of 0.00% beat Dare Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	-803.80%	-748.30%	-38.75%
Alterity Therapeutics	N/A	N/A	N/A

6.7% of Dare Bioscience shares are owned by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are owned by institutional investors. 3.4% of Dare Bioscience shares are owned by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Dare Bioscience has higher revenue and earnings than Alterity Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.37M	10.50	-$13.40M	-$0.70	N/A
Alterity Therapeutics	N/A	N/A	-$15.88M	N/A	N/A

In the previous week, Dare Bioscience had 4 more articles in the media than Alterity Therapeutics. MarketBeat recorded 6 mentions for Dare Bioscience and 2 mentions for Alterity Therapeutics. Alterity Therapeutics' average media sentiment score of 0.89 beat Dare Bioscience's score of 0.31 indicating that Alterity Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dare Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alterity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dare Bioscience currently has a consensus target price of $6.50, indicating a potential upside of 791.63%. Alterity Therapeutics has a consensus target price of $10.00, indicating a potential upside of 255.87%. Given Dare Bioscience's higher probable upside, research analysts clearly believe Dare Bioscience is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Alterity Therapeutics beats Dare Bioscience on 7 of the 13 factors compared between the two stocks.

How does Dare Bioscience compare to InterCure?

Dare Bioscience (NASDAQ:DARE) and InterCure (NASDAQ:INCR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

InterCure has higher revenue and earnings than Dare Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.37M	10.50	-$13.40M	-$0.70	N/A
InterCure	$270.20M	0.19	-$10.37M	N/A	N/A

Dare Bioscience currently has a consensus target price of $6.50, indicating a potential upside of 791.63%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Dare Bioscience is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Dare Bioscience has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market. Comparatively, InterCure has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market.

6.7% of Dare Bioscience shares are held by institutional investors. Comparatively, 8.3% of InterCure shares are held by institutional investors. 3.4% of Dare Bioscience shares are held by insiders. Comparatively, 0.2% of InterCure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Dare Bioscience had 5 more articles in the media than InterCure. MarketBeat recorded 6 mentions for Dare Bioscience and 1 mentions for InterCure. InterCure's average media sentiment score of 1.82 beat Dare Bioscience's score of 0.31 indicating that InterCure is being referred to more favorably in the news media.

Company	Overall Sentiment
Dare Bioscience	Neutral
InterCure	Very Positive

InterCure has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. InterCure's return on equity of 0.00% beat Dare Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	-803.80%	-748.30%	-38.75%
InterCure	N/A	N/A	N/A

Summary

InterCure beats Dare Bioscience on 8 of the 14 factors compared between the two stocks.

How does Dare Bioscience compare to Talphera?

Dare Bioscience (NASDAQ:DARE) and Talphera (NASDAQ:TLPH) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

Dare Bioscience has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.37M	10.50	-$13.40M	-$0.70	N/A
Talphera	$30K	1,834.15	-$14.29M	-$0.27	N/A

Dare Bioscience presently has a consensus price target of $6.50, indicating a potential upside of 791.63%. Talphera has a consensus price target of $3.00, indicating a potential upside of 183.02%. Given Dare Bioscience's stronger consensus rating and higher possible upside, research analysts clearly believe Dare Bioscience is more favorable than Talphera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Dare Bioscience had 4 more articles in the media than Talphera. MarketBeat recorded 6 mentions for Dare Bioscience and 2 mentions for Talphera. Talphera's average media sentiment score of 1.25 beat Dare Bioscience's score of 0.31 indicating that Talphera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dare Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Talphera	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dare Bioscience has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market. Comparatively, Talphera has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market.

Talphera has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. Talphera's return on equity of -87.28% beat Dare Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	-803.80%	-748.30%	-38.75%
Talphera	N/A	-87.28%	-51.36%

6.7% of Dare Bioscience shares are owned by institutional investors. Comparatively, 37.7% of Talphera shares are owned by institutional investors. 3.4% of Dare Bioscience shares are owned by insiders. Comparatively, 3.5% of Talphera shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Dare Bioscience and Talphera tied by winning 7 of the 14 factors compared between the two stocks.

Get Dare Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DARE vs. The Competition

Export

Metric	Dare Bioscience	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$14.56M	$12.65B	$7.43B	$12.93B
Dividend Yield	N/A	2.63%	2.52%	19.59%
P/E Ratio	-1.06	805.28	274.96	25.39
Price / Sales	10.66	837.08	608.73	90.53
Price / Cash	N/A	84.08	76.68	52.75
Price / Book	3.70	9.32	10.32	6.02
Net Income	-$13.40M	$2.83B	$3.49B	$380.68M
7 Day Performance	-4.17%	-3.43%	-2.54%	-3.01%
1 Month Performance	1.36%	-7.27%	-6.87%	-5.59%
1 Year Performance	-63.90%	-5.47%	1.81%	-5.23%

Dare Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DARE Dare Bioscience	2.5967 of 5 stars	$0.74 +1.5%	$6.50 +778.4%	-64.6%	$14.56M	$1.37M	N/A	24
HRTX Heron Therapeutics	2.0905 of 5 stars	$0.33 -10.4%	$2.00 +503.0%	-72.6%	$62.97M	$154.90M	N/A	128	Options Volume Gap Up
ELOX Eloxx Pharmaceuticals	2.8987 of 5 stars	$15.13 -1.8%	$38.33 +153.4%	N/A	$61.13M	$6.36M	N/A	7	News Coverage Analyst Forecast
ATHE Alterity Therapeutics	3.3209 of 5 stars	$3.37 +4.7%	$10.00 +196.7%	-40.6%	$61.09M	N/A	N/A	11	Analyst Upgrade Gap Down
INCR InterCure	0.9654 of 5 stars	$5.39 -1.2%	N/A	-42.3%	$58.89M	$270.20M	35.90	285	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DARE) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dare Bioscience (DARE) Competitors

DARE vs. HRTX, ELOX, ATHE, INCR, and TLPH

How does Dare Bioscience compare to Heron Therapeutics?

Summary

How does Dare Bioscience compare to Eloxx Pharmaceuticals?

Summary

How does Dare Bioscience compare to Alterity Therapeutics?

Summary

How does Dare Bioscience compare to InterCure?

Summary

How does Dare Bioscience compare to Talphera?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DARE vs. The Competition

Dare Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dare Bioscience (DARE) Competitors

DARE vs. HRTX, ELOX, ATHE, INCR, and TLPH

How does Dare Bioscience compare to Heron Therapeutics?

Is HRTX or DARE more profitable?

Does the media favor HRTX or DARE?

Which has stronger valuation & earnings, HRTX or DARE?

Do analysts recommend HRTX or DARE?

Which has more risk and volatility, HRTX or DARE?

Do institutionals and insiders have more ownership in HRTX or DARE?

Summary

How does Dare Bioscience compare to Eloxx Pharmaceuticals?

Which has more volatility & risk, DARE or ELOX?

Do institutionals & insiders have more ownership in DARE or ELOX?

Does the media refer more to DARE or ELOX?

Do analysts prefer DARE or ELOX?

Is DARE or ELOX more profitable?

Which has higher valuation & earnings, DARE or ELOX?

Summary

How does Dare Bioscience compare to Alterity Therapeutics?

Which has more volatility & risk, DARE or ATHE?

Is DARE or ATHE more profitable?

Do insiders and institutionals believe in DARE or ATHE?

Which has higher earnings and valuation, DARE or ATHE?

Does the media refer more to DARE or ATHE?

Do analysts recommend DARE or ATHE?

Summary

How does Dare Bioscience compare to InterCure?

Which has preferable earnings & valuation, DARE or INCR?

Do analysts prefer DARE or INCR?

Which has more risk and volatility, DARE or INCR?

Do institutionals & insiders hold more shares of DARE or INCR?

Does the media refer more to DARE or INCR?

Is DARE or INCR more profitable?

Summary

How does Dare Bioscience compare to Talphera?

Which has preferable valuation & earnings, DARE or TLPH?

Do analysts recommend DARE or TLPH?

Does the media favor DARE or TLPH?

Which has more volatility & risk, DARE or TLPH?

Is DARE or TLPH more profitable?

Do insiders & institutionals believe in DARE or TLPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DARE vs. The Competition

Dare Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools